This activity is for healthcare professionals outside of the UK.

This activity is provided by an independent medical education grant from Coherus BioSciences.

The activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go
    • CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Barbara Burtness

    Yale School of Medicine, New Haven, CT, USA

    Prof. Barbara Burtness is an Anthony N Brady Professor of Medicine at the Yale School of Medicine, and Chief Translational Research Officer, Associate Director for Translational Science, and Chief, Division of Head and Neck/Sarcoma Oncology at the Yale Cancer Center, New Haven, CT, USA. read more

    Prof. Burtness serves as co-leader of the Yale Cancer Center Developmental Therapeutics Program and director of the Yale Head and Neck Specialized Program of Research Excellence.

    Prof. Burtness is internationally recognized for her research in head and neck cancer. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee, and leads national and international trials of targeted therapy in head and neck cancer.

    Prof. Burtness has served on the editorial board for a number of journals, including the Journal of Clinical Oncology and Clinical Cancer Research. She has contributed to a number of practice guidelines, standards and consensus statements in head and neck cancer, and has also published widely on the topic, with over 200 publications.

    Prof. Barbara Burtness discloses: Employee or independent contractor relationships with ALX Oncology and Merus. Advisory board or panel fees from AstraZeneca, Coherus BioSciences, Genmab, GSK, Merck KGaA and Rakuten Medical. Consultancy fees from IO Biotech, Merus and Vaccinex, Inc (relationships terminated). Speaker Bureau fees from Coherus BioSciences.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    SEE ALL CHAPTERS
    Start activity
     
    Focus Questions
    What are the current unmet treatment needs of patients with RM-NPC in the first and later lines?
    What are the key clinical data supporting the use of ICIs in the first-line setting for RM-NPC?
    What are some of the key considerations for identifying patients with RM-NPC who may particularly benefit from treatment with an ICI in the first line?
    What are the key clinical data supporting the use of ICIs to treat patients with RM-NPC in the second- and later-line settings?
    How do you identify patients with RM-NPC who are likely to benefit from treatment with ICIs in the second- and later-line settings?
    What are some of your key recommendations for monitoring for and managing the side effects associated with ICIs when used to treat patients with RM-NPC?
    How would your management approach to RM-NPC differ based on the presence/absence of Epstein-Barr virus (EBV) infection?
    Which investigational immunotherapy approaches are showing particular promise for the future treatment of patients with RM-NPC in the first- and later-line settings?
    Take CE/CME Test
    Head and Neck Cancer, Immunotherapy CE/CME accredited

    touchFOCUS
    Quickfire Q&A with expert faculty. Close

    Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors

    Take CE/CME Test

    Prof. Barbara Burtness is an Anthony N Brady Professor of Medicine at the Yale School of Medicine, and Chief Translational Research Officer, Associate Director for Translational Science, and Chief, Division of Head and Neck/Sarcoma Oncology at the Yale Cancer Center, New Haven, CT, USA. read more

    Prof. Burtness serves as co-leader of the Yale Cancer Center Developmental Therapeutics Program and director of the Yale Head and Neck Specialized Program of Research Excellence.

    Prof. Burtness is internationally recognized for her research in head and neck cancer. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee, and leads national and international trials of targeted therapy in head and neck cancer.

    Prof. Burtness has served on the editorial board for a number of journals, including the Journal of Clinical Oncology and Clinical Cancer Research. She has contributed to a number of practice guidelines, standards and consensus statements in head and neck cancer, and has also published widely on the topic, with over 200 publications.

    Prof. Barbara Burtness discloses: Employee or independent contractor relationships with ALX Oncology and Merus. Advisory board or panel fees from AstraZeneca, Coherus BioSciences, Genmab, GSK, Merck KGaA and Rakuten Medical. Consultancy fees from IO Biotech, Merus and Vaccinex, Inc (relationships terminated). Speaker Bureau fees from Coherus BioSciences.

    Faculty Podcast Featured
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Discuss the role of immune checkpoint inhibitors in the first-line setting for recurrent or metastatic nasopharyngeal carcinoma
    • Summarize the use of immune checkpoint inhibitors in the second- and subsequent-line treatment of recurrent or metastatic nasopharyngeal carcinoma
    Overview

    In this interview, Prof. Barbara Burtness answers a series of questions focused on the evolving role of immune checkpoint inhibitors (ICIs) in the first- and subsequent-line settings for recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    This activity has been designed to meet the educational needs of medical oncologists, including head and neck cancer specialists, and oncology nurses involved in the management of recurrent/metastatic nasopharyngeal carcinoma.

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Prof. Barbara Burtness discloses: Employee or independent contractor relationships with ALX Oncology and Merus. Advisory board or panel fees from AstraZeneca, Coherus BioSciences, Genmab, GSK, Merck KGaA and Rakuten Medical. Consultancy fees from IO Biotech, Merus and Vaccinex, Inc (relationships terminated). Speaker Bureau fees from Coherus BioSciences.

    Content reviewer

    Danielle Walker, DNP, APRN, AGNP-C, nurse reviewer and planner, has no financial interests/relationships or affiliations in relation to this activity.

    Touch Medical Contributors

    Christina Mackins-Crabtree has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Nurses

    USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    A maximum of 0.5 contact hours may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

    This activity is awarded 0.5 ANCC pharmacotherapeutic contact hour.

    Date of original release: 26 September 2024. Date credits expire: 26 September 2025.

    If you have any questions regarding credit, please contact cpdsupport@usf.edu

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit

    You may also be interested in...

    touchFOCUS

    Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchPANEL DISCUSSION

    Immunogenicity of immune checkpoint inhibitors: What are the implications for clinical practice?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy

    GO TO HUB

    CONFERENCE HUB

    Omid Hamid, ASCO 2021: Nemvaleukin Alfa and the ARTISTRY-2 Trial

    GO TO HUB

    JOURNALS

    Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy – the PSV™ Platform

    GO TO ARTICLE

    JOURNALS

    Recent Advances in Oral Oncology

    GO TO ARTICLE

    Topics covered in this activity

    Head and Neck Cancer / Immunotherapy
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 9 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is funded by:

    An independent medical education grant from Coherus BioSciences.
    This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    This content is intended for healthcare professionals outside the UK only.

    Date of original release: 26 September 2024. Date credits expire: 26 September 2025.

    Claim Credit
    touchFOCUS
    Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors
    0.5 CE/CME credit
    Question 1/5
    Based on the phase III JUPITER-02 clinical trial, what were the approximate 3-year overall survival rates for patients with RM-NPC treated first line with toripalimab + GC versus placebo + GC?

    GC, gemcitabine-cisplatin; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma.

    The JUPITER-02 trial assessed the efficacy and safety of first-line toripalimab + GC (n=146) versus placebo + GC (n=143) in patients with RM-NPC.1 In the final overall survival analysis, the 3-year overall survival rate for toripalimab was 65.1 % versus 49.2% for placebo.2

    Abbreviations
    GC, gemcitabine-cisplatin; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma.

    References

    1. Mai HQ, et al. JAMA. 2023;330:1961–70.
    2. Mai HQ, et al. J Clin Oncol. 2023;41(Suppl. 16):6009.
    Question 2/5
    Which of the following RM-NPC patient profiles would you consider the most suitable candidate to receive an ICI + CT in the first-line setting?

    CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; PD-L1, programmed death ligand 1; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma.

    The NCCN guidelines indicate toripalimab or other PD-1 inhibitor (e.g. pembrolizumab or nivolumab) + GC-based CT as a preferred first-line therapeutic regimen for recurrent, unresectable, oligometastatic or metastatic disease (with no surgery or RT option).1

    Exclusion criteria in the pivotal trials investigating ICI + CT as first-line treatment in RM-NPC included: recurrence amenable to resection, prior ICI therapy, history of autoimmune disease and ECOG PS >1.2–4

    Abbreviations
    CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; GC, gemcitabine-cisplatin; ICI, immune checkpoint inhibitor; PD-1, programmed death 1; PD-L1, programmed death ligand 1; NCCN, National Comprehansive Cancer Network; PFS, progression-free survival; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma; RT, radiotherapy; TPS, tumour proportion score.

    References

    1. NCCN Guidelines®. Head and Neck Cancers Version 4.2024 — May 1, 2024. Available at: www.nccn.org (accessed 11 September 2024).
    2. Mai HQ, et al. JAMA. 2023;330:1961–70.
    3. Yang Y, et al. Lancet Oncol. 2021;22:1162–74.
    4. Yang Y, et al. Cancer Cell. 2023;41:1061–72.
    Question 3/5
    You are discussing treatment options with a patient with RM-NPC who also has Crohn's disease. The patient would like to be treated with an ICI + GC because he has heard that outcomes tend to be better than for GC alone. How do you counsel him?

    GC, gemcitabine-cisplatin; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma.

    Patients with a history of autoimmune disease may be more likely to discontinue ICI treatment due to an irAE, or be at higher risk of an irAE specific to their condition (e.g., colitis in a patient with a history of inflammatory bowel disease).1 Reflecting these concerns, patients with autoimmune disease, other than stable hypothyroidism or type I diabetes, and patients who required systemic immunosuppression were ineligible for the pivotal JUPITER-02 trial of toripalimab + GC in patients with RM-NPC.2

    Abbreviations
    GC, gemcitabine-cisplatin; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma.

    References

    1. Conroy M, Naidoo J. Nat Commun. 2022;13:392.
    2. FDA. Toripalimab PI. 2023. Available at: https://bit.ly/3Zkk7OJ (accessed 11 September 2024).
    Question 4/5
    When evaluating a patient with RM-NPC, which of the following specific clinical/biological characteristics would favour your incorporation of an ICI in the second-line treatment setting?

    ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; PD-L1, programmed death ligand 1; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma; TMB, tumour mutational burden; TPS, tumour proportion score.

    A recent meta-analysis suggested that first-line immunotherapy could significantly improve PFS in patients with RM-NPC, regardless of the PD-L1 expression levels. However, positive PD-L1 expression (≥1%) might be a potential predictive biomarker for a better overall response to immunotherapy in patients with RM-NPC in subsequent-line settings.

    Abbreviations
    PD-L1, programmed death ligand 1; PFS, progression-free survival; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma.

    Reference

    Liu X, et al. Front Oncol. 2024;14:1386381.

    Question 5/5
    What role do the clinical trials suggest ICI monotherapy plays in the treatment of patients with RM-NPC in the second- or later-line settings?

    ICI, immune checkpoint inhibitor; mPFS, median progression-free survival; mOS, median overall survival; ORR, objective response rate; RM-NPC, recurrent or metastatic nasopharyngeal carcinoma.

    Clinical trials of pembrolizumab,1 nivolumab2,3 and toripalimab4 reported ORRs of approximately 20%. Based on these results, they are included in the NCCN guidelines as possible treatment options in the second or later line.5

    Abbreviations
    NCCN, National Comprehansive Cancer Network; ORR, objective response rate.

    References

    1. Chan ATC, et al. Ann Oncol. 2023;34:251–61.
    2. DeLord JP, et al. J Clin Oncol. 2017:35(15_Suppl.):6025.
    3. Ma BBY, et al. J Clin Oncol. 2018;36:1412–18.
    4. Wang FH, et al. J Clin Oncol. 2021;39:704–12.
    5. NCCN Guidelines®. Head and Neck Cancers Version 4.2024 — May 1, 2024. Available at: www.nccn.org (accessed 11 September 2024).
    Back to Activity

    You may also be interested in...

    touchEXPERT OPINIONS

    Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer

    GO TO HUB

    touchPANEL DISCUSSION

    What is the current state of play of CAR T-cell therapy for B-cell malignancies? Focus on patient selection, safety and new indications

    LAUNCH ACTIVITY
    Aapro_T.png

    CONFERENCE HUB

    Matti Aapro, ESMO 2018 – Immunotherapy in Elderly Patients

    GO TO HUB

    JOURNALS

    The International Union Against Cancer

    GO TO ARTICLE

    JOURNALS

    The International Union Against Cancer

    GO TO ARTICLE
    This activity is funded by:

    An independent medical education grant from Coherus BioSciences.
    This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    This content is intended for healthcare professionals outside the UK only.

    Date of original release: 26 September 2024. Date credits expire: 26 September 2025.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72